Bar chart: Gilead Yescarta versus Tecartus Sales for Gilead Sciences. Q2 2025-Q2 2026, values in usd_millions. In Q2 2026: Yescarta 346, Tecartus 70.
Gilead Livdelzi Sales
Line chart: Gilead Livdelzi Sales for Gilead Sciences. Q2 2025-Q2 2026, values in usd_millions. Q2 2026 68%, Q2 2025 32%.
Livdelzi
Gilead Yeztugo PrEP Sales
Line chart: Gilead Yeztugo PrEP Sales for Gilead Sciences. Q2 2025-Q2 2026, values in usd_millions. Q2 2026 94%, Q2 2025 6%.
Yeztugo
Employee Count
Line chart: Employee Count for Gilead Sciences. 1996-2025. Employees: 248 in 1996 to 17,000 in 2025, peaking at 18,000 in 2023.
Employees
Gilead HIV Product Mix
Bar chart: Gilead HIV Product Mix for Gilead Sciences. Q2 2025-Q2 2026, values in usd_millions. In Q2 2026: Biktarvy 3,772, Descovy 967, Yeztugo 232, Genvoya 289, Odefsey 239, Symtuza share and other HIV 194.
Revenue by Product/Service
Bar chart: Revenue by Product/Service for Gilead Sciences. 2021-Q3-2026-Q2, values in B. In 2026-Q2: Products, Other HIV 5.693, Cell Therapy Products, Total Cell Therapy Product Sales 0.487, Trodelvy 0.457, Other Products, Total Other product sales 0.161, Veklury 0.023, Liver Disease 0, and 3 more.
Revenue by Geography
Bar chart: Revenue by Geography for Gilead Sciences. 2021-Q3-2026-Q2, values in B. In 2026-Q2: United States 5.603, Europe 1.324, Other International 0.876.